List of Excipients in Branded Drug VELPHORO

Velphoro Excipient Strategy and Commercial Opportunities in Sucroferric Oxyhydroxide

Last updated: August 13, 2026

Velphoro is a chewable phosphate binder based on sucroferric oxyhydroxide, marketed primarily by CSL Vifor for adults and certain pediatric patients with chronic kidney disease on dialysis. Its excipient strategy supports three commercial objectives: making a high-dose inorganic complex chewable, improving palatability, and maintaining a lower tablet burden than several competing phosphate binders. The strongest opportunities are in taste-masked generics or 505(b)(2) products, alternative flavors, pediatric presentations, regional manufacturing, and excipient platforms that improve dose uniformity and mouthfeel.

What is Velphoro and how does its formulation work?

Velphoro contains sucroferric oxyhydroxide, an iron-based phosphate binder. The active complex binds dietary phosphate in the gastrointestinal tract and is minimally absorbed systemically. The product is administered with meals and is supplied as a chewable tablet rather than a conventional swallowable tablet or capsule.[1]

Velphoro formulation profile

Attribute	Velphoro profile
Active ingredient	Sucroferric oxyhydroxide
Therapeutic class	Iron-based phosphate binder
Dosage form	Chewable tablet
US strength	500 mg iron per tablet
Typical starting dose	1,500 mg iron daily, divided with meals
Dose adjustment	Titrated according to serum phosphorus
Administration	Chewed with meals; tablets are not intended to be swallowed whole
Main patient population	Chronic kidney disease patients on dialysis
Pediatric use	FDA labeling includes patients 9 years and older on dialysis
Commercial owner	CSL Vifor
Key formulation issue	Palatability and chewability at a high inorganic active load

The 500 mg iron label strength does not represent 500 mg of pure elemental iron powder. It reflects the amount of iron contained in the sucroferric oxyhydroxide complex. Each tablet contains substantially more total complex mass than the labeled iron quantity, creating a formulation challenge involving tablet size, density, friability, and taste.[1]

What excipients are used in Velphoro chewable tablets?

Velphoro uses a relatively compact excipient system. Public product information identifies microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide or colloidal anhydrous silica, and flavoring components. Regional labels may describe the excipient composition differently, including the use of maize or corn starch.[1,2]

Functional role of the excipients

Excipient class	Likely formulation function	Commercial relevance
Microcrystalline cellulose	Filler, compression aid, structural matrix	Supports tablet strength while controlling tablet size
Maize or corn starch	Filler, binder, or disintegration support, depending on grade and process	Enables regional formulation adaptation
Crospovidone	Wicking and disintegration support	Helps break down a chewable matrix after mastication
Magnesium stearate	Lubricant	Reduces sticking and ejection force during compression
Colloidal silicon dioxide	Glidant and flow aid	Improves flow of a dense, iron-containing blend
Flavoring	Taste masking and acceptability	Central to repeat use and adherence
Sweetening system, where used	Reduces metallic or mineral taste	Potential target for reformulation and product differentiation

The excipient system is not simply a conventional tablet platform. Sucroferric oxyhydroxide is an insoluble, iron-containing complex with a strong mineral and metallic sensory profile. Excipients must support high drug loading while producing a tablet that patients can chew repeatedly, often several times daily.

Why is taste masking the central excipient issue?

Taste is the most commercially important formulation barrier for Velphoro. Phosphate binders are chronic-use products, and patients may take them with every meal. A formulation that has acceptable hardness but poor taste can produce low persistence, tablet avoidance, or administration with insufficient food.

Sensory challenges

Sucroferric oxyhydroxide can create:

• Metallic and earthy taste
• Chalky or gritty mouthfeel
• Residual bitterness after chewing
• Perception of dryness
• Flavor fatigue during long-term treatment

The existing fruit-punch flavoring reflects a practical approach: use a strong, recognizable flavor to compete with the active complex rather than relying solely on sweeteners. Flavor intensity, acid balance, aroma release, and particle-size control are likely more important than sweetness alone.

Commercial excipient opportunities in taste masking

The highest-value opportunities include:

1. Encapsulated flavors. Microencapsulated fruit, berry, citrus, or confectionery flavors could improve flavor persistence and reduce direct contact between the active particles and taste receptors.

2. Polymer coating of active particles. Thin coating systems based on food-compatible or pharmaceutical polymers could reduce metallic taste. The coating must not materially impair phosphate-binding performance.

3. Ion-exchange or adsorption-based masking. Taste-masking polymers and adsorbents may reduce free metal-ion interaction in the oral cavity. Their impact on gastrointestinal phosphate binding requires direct performance testing.

4. Cooling or sensory-modifying systems. Mint, citrus, or cooling flavors may reduce metallic perception, although these profiles may not be acceptable to all dialysis patients.

5. Particle engineering. Larger agglomerates can reduce the surface area exposed during chewing, while porous granules may improve disintegration after swallowing. The optimal design must balance mouthfeel, phosphate-binding kinetics, and dose uniformity.

A successful taste-masking platform could have licensing value beyond Velphoro. The same technology may apply to iron salts, mineral supplements, potassium binders, calcium formulations, and other chronic-use gastrointestinal products.

How does Velphoro’s excipient strategy reduce tablet burden?

Velphoro was positioned partly around tablet burden. Patients receiving dialysis commonly take phosphate binders with meals, and total daily tablet counts can be substantial. Velphoro’s chewable format and relatively high phosphate-binding capacity per tablet can reduce the number of units compared with some sevelamer regimens, although actual tablet counts depend on serum phosphorus, diet, and titration.[3]

Competitive dosage-form comparison

Product	Active class	Dosage form	Main excipient challenge	Tablet-burden position
Velphoro	Sucroferric oxyhydroxide	Chewable tablet	Metallic taste, mineral mouthfeel, dense active	Designed to reduce unit burden
Renvela/Renagel	Sevelamer carbonate or hydrochloride	Tablet or powder	Large dose mass, swelling, gritty suspension	Often high dose burden
Fosrenol	Lanthanum carbonate	Chewable tablet or powder	Metallic/mineral taste and chewability	Chewable alternative
Auryxia	Ferric citrate	Tablet	High tablet count and iron-related gastrointestinal effects	Tablet-based iron binder
Calcium acetate products	Calcium salts	Capsule or tablet	Calcium exposure and dose burden	Low-cost generic competition
Tenapanor	NHE3 inhibitor	Tablet	Different mechanism and gastrointestinal tolerability	Non-binder alternative

Velphoro’s excipient strategy must preserve the commercial advantage of a compact chronic-use regimen. Adding large quantities of sweeteners, coating polymers, or bulking agents could undermine that advantage by increasing tablet size or daily mass.

What formulation patents and intellectual property protect Velphoro?

Velphoro’s intellectual property position is likely to involve multiple layers rather than a single excipient patent. The relevant categories include the sucroferric oxyhydroxide complex, manufacturing conditions, pharmaceutical compositions, chewable dosage forms, and therapeutic use in hyperphosphatemia associated with chronic kidney disease.

Core patent categories

Patent category	Potential protected subject matter	Commercial effect
Composition patents	Sucroferric oxyhydroxide or defined iron oxyhydroxide-sucrose complexes	Protect the active pharmaceutical complex
Process patents	Precipitation, drying, milling, granulation, and control of iron or sucrose ratios	Can complicate non-infringing manufacture
Formulation patents	Chewable tablets, excipient ratios, density, hardness, or disintegration	May block direct formulation copying
Method-of-use patents	Treatment of hyperphosphatemia in dialysis patients	Can affect label scope and skinny-label strategy
Manufacturing-quality patents	Control of particle size, iron oxidation state, or phosphate-binding capacity	Creates analytical and CMC barriers
Trade secrets	Flavor system, processing parameters, blend order, and scale-up conditions	May remain relevant after formal patent expiry

Sucroferric oxyhydroxide is a complex inorganic-organic material rather than a simple, sharply defined small molecule. The quality of a competing product may depend on particle morphology, iron oxidation state, sucrose content, hydration, surface area, and phosphate-binding performance. Those parameters can create regulatory and manufacturing barriers even when broad composition claims are vulnerable.

How strong is the Velphoro patent estate?

The strongest practical protection is likely to come from the combination of composition, process, formulation, and regulatory complexity. A competitor may avoid one claim set but still face difficulty reproducing the active complex and demonstrating pharmaceutical equivalence.

Excipient patents alone are unlikely to provide the principal barrier. Flavoring and ordinary tablet excipients are generally replaceable. A stronger formulation position would require claims directed to a defined combination of:

• Sucroferric oxyhydroxide particle characteristics
• High active loading
• Chewable tablet mechanical properties
• Taste-masking architecture
• Phosphate-binding performance
• Stability under long-term storage

The commercial strength of any patent estate depends on claim scope, prosecution history, terminal disclaimers, Orange Book listing, and litigation outcomes. Patent expiry dates should be assessed family by family rather than inferred from the 2013 FDA approval date.[1,4]

When does Velphoro lose exclusivity?

Velphoro’s regulatory exclusivity and patent exclusivity are separate issues. FDA approval occurred in 2013, but the potential timing of generic or follow-on entry depends on listed patents, any pediatric exclusivity, regulatory exclusivity, litigation, settlements, and the pathway selected by a competitor.[1]

Exclusivity considerations

Issue	Relevance to Velphoro
FDA approval date	November 2013
Small-molecule ANDA pathway	May be difficult because the active is a complex iron-based material
505(b)(2) pathway	Potentially relevant for a product relying partly on FDA findings while using a different formulation or presentation
Paragraph IV challenge	Possible if a competitor seeks approval before listed patents expire
Pediatric exclusivity	Could add six months if formally granted for qualifying studies
Orange Book status	Must be evaluated against current FDA listings and patent certifications
Biosimilar pathway	Not the expected route for this product
Generic substitution	May depend on therapeutic equivalence, dosage form, formulation, and state substitution rules

Are biosimilars a risk for Velphoro?

No conventional biosimilar pathway is expected. Velphoro is not a biologic and is not regulated as a protein-based reference product under the FDA biosimilar framework. Competitive risk is more likely to come from an ANDA, a 505(b)(2) application, a substitutable phosphate binder, or a therapeutically differentiated product such as tenapanor.[5]

The regulatory challenge is proving sameness or sufficient comparability for a complex, poorly characterized active. A competitor may need to demonstrate more than matching the nominal iron content. Relevant attributes may include:

• Iron oxidation state
• Sucrose-to-iron ratio
• Particle-size distribution
• Surface area
• Hydration state
• Phosphate-binding capacity
• Dissolution or extraction behavior
• Elemental impurity profile
• Stability and degradation behavior

These attributes create an opportunity for analytical laboratories, reference-standard providers, and excipient developers with experience in complex inorganic products.

Which companies are challenging Velphoro commercially?

Velphoro competes across several segments rather than against one product. Sevelamer products remain established in dialysis. Lanthanum carbonate and ferric citrate compete through chewability or iron-based mechanisms. Calcium acetate products compete primarily on price. Tenapanor competes through a non-binder mechanism and a lower tablet count.

Competitive landscape

Competitor	Company or originator	Strategic threat
Renvela and generic sevelamer carbonate	Sanofi originator; multiple generic manufacturers	Broad generic availability and clinical familiarity
Fosrenol	Takeda originator; generic lanthanum products	Chewable phosphate-binder experience
Auryxia	Keryx, now within Akebia commercial portfolio	Iron-based positioning and oral tablet format
Calcium acetate	Multiple generic manufacturers	Low acquisition cost
Xphozah/tenapanor	Ardelyx	Mechanism-based alternative with lower pill burden
Generic and regional phosphate binders	Multiple manufacturers	Price pressure and tender access

Velphoro’s differentiation depends on the balance between pill burden, tolerability, cost, and clinical preference. Excipients can directly influence this balance by determining whether the product is accepted as a chewable chronic therapy.

What commercial opportunities exist for Velphoro excipients?

The addressable opportunity is broader than supplying commodity excipients. The strongest value lies in formulation systems that solve a product-specific problem and can be protected through know-how, process control, or composition claims.

1. Taste-masked generic or follow-on product

A competitor could develop a chewable sucroferric oxyhydroxide product with improved flavor, reduced grit, or a smaller tablet. The commercial proposition would be strongest if the product preserves the original dosing frequency while improving patient acceptance.

Potential value drivers include:

• Better palatability
• Lower tablet mass
• Reduced flavor fatigue
• Lower manufacturing cost
• Regional flavor customization
• Stable performance across different excipient suppliers

2. Pediatric formulation

Velphoro’s pediatric labeling creates a defined opportunity for age-appropriate dosage forms. Pediatric patients may have greater difficulty chewing large tablets and may require flexible dosing.

Potential products include:

• Mini-chewable tablets
• Scored tablets
• Granules in sachets
• Sprinkle formulations
• Oral powders mixed with soft food
• Lower-strength tablets

Pediatric excipients must address safety, sugar content, allergen control, dental exposure, and taste. A multiparticulate product could improve dose flexibility but would require careful control of segregation and phosphate-binding equivalence.

3. Flavor portfolio expansion

A single fruit-punch profile limits geographic and demographic flexibility. A portfolio could include berry, citrus, tropical fruit, or neutral flavors. Flavor expansion is commercially attractive because it may avoid changing the active complex while improving market segmentation.

The main risks are stability, interaction with iron, color changes, and inconsistent sensory release after storage.

4. Regional manufacturing and procurement

Velphoro’s excipient list contains widely available materials, which supports supply-chain flexibility. Local sourcing of microcrystalline cellulose, starch, crospovidone, silica, and flavoring can reduce freight costs and improve tender competitiveness.

The key constraint is maintaining equivalent critical material attributes. Changes in cellulose morphology, crospovidone particle size, silica surface area, or flavor composition can alter compression, disintegration, and taste.

5. Direct-compression and continuous-manufacturing platforms

A dense inorganic active can create poor flow and segregation. High-functionality excipients designed for direct compression may reduce granulation steps and improve throughput. Continuous manufacturing could help control blend uniformity and reduce batch-to-batch variability.

Commercially relevant excipient technologies include:

• Spray-dried cellulose systems
• Co-processed cellulose and starch
• Low-dust glidant systems
• Functionalized crospovidone
• Granulated flavor systems
• Flow-enhancing mineral-compatible excipients

6. Contract development and manufacturing services

CDMOs with expertise in chewable tablets and complex inorganic actives can offer development services to generic or 505(b)(2) sponsors. Services may include:

• Active characterization
• Excipient compatibility screening
• Taste-masking development
• Chewable-tablet scale-up
• Comparative dissolution or phosphate-binding testing
• Stability programs
• Process validation
• Regulatory CMC support

This opportunity is less exposed to the success of one branded product because the same capabilities can support lanthanum, ferric, calcium, and potassium-binding products.

What manufacturing and IP barriers affect commercial entry?

The major manufacturing barrier is not compression alone. It is reproducible control of a complex active with high loading and strong sensory attributes.

Critical quality attributes

A development program should control:

• Assay and elemental iron content
• Iron oxidation state
• Sucrose content and chemical association
• Particle-size distribution
• Specific surface area
• Bulk density and flow
• Water content
• Phosphate-binding capacity
• Tablet hardness and friability
• Chewability and mouthfeel
• Flavor stability
• Microbial quality
• Elemental impurities

A formulation that matches the listed excipient names but produces different active morphology may not be clinically or regulatorily equivalent. This creates a defensible technical barrier for the originator and a specialized development opportunity for competitors.

What is the revenue exposure and commercial importance of Velphoro?

Velphoro is a strategic product in the phosphate-binder market because dialysis patients use phosphate binders chronically and treatment is linked to meal frequency. CSL Vifor identifies Velphoro as one of its major nephrology products, alongside Veltassa and other renal therapies.[6]

Revenue exposure is driven by:

• Number of dialysis patients treated
• Share within non-calcium phosphate binders
• Reimbursement and formulary placement
• Average daily tablet count
• Generic sevelamer pricing
• Adoption of tenapanor
• Regional dialysis-provider purchasing
• Patient persistence and tolerability

The product’s commercial durability depends on more than patent protection. A palatable chewable formulation, established prescribing behavior, and dialysis-center access can support sales after core patent expiry. Conversely, a low-cost generic or a better-tolerated alternative could erode volume before complete loss of legal exclusivity.

Key Takeaways

• Velphoro is a chewable sucroferric oxyhydroxide phosphate binder with a high inorganic active load.
• Its excipient system is built around compression, flow, disintegration, lubrication, and flavor management.
• Taste masking is the most important formulation opportunity because metallic taste and mineral mouthfeel affect chronic adherence.
• The strongest follow-on opportunities are improved chewable tablets, pediatric presentations, sachets, granules, and regional flavor variants.
• Generic entry may require a complex regulatory strategy because sucroferric oxyhydroxide is an iron-based complex rather than a simple molecular active.
• Biosimilar competition is not the expected risk. ANDA, 505(b)(2), generic phosphate binders, and non-binder alternatives are more relevant.
• Patent risk should be assessed across composition, process, formulation, method-of-use, Orange Book listing, and litigation history.
• Commodity excipients alone have limited differentiation. Co-processed excipients, encapsulated flavors, particle engineering, and complex-inorganic manufacturing know-how offer greater commercial value.
• The most defensible commercial platform is a taste-masking and high-loading chewable technology that can be applied across phosphate binders and other mineral-based therapies.

FAQs

Can Velphoro be reformulated as a swallowable tablet?

Yes, but a swallowable product would change the administration profile and could require a new regulatory pathway. It would also remove part of Velphoro’s chewable differentiation and may not improve the metallic-taste problem if the tablet is swallowed incompletely.

Which excipient is most important for Velphoro taste masking?

Flavoring is the most visible component, but taste performance depends on the combined effect of flavor, particle engineering, granulation, sweetening, and tablet disintegration. A stronger flavor alone may not eliminate metallic or gritty perception.

Is a Velphoro generic likely to use the same excipients?

Not necessarily. A generic or 505(b)(2) developer may use different fillers, binders, lubricants, flavors, or taste-masking systems. The product must still meet applicable pharmaceutical equivalence, quality, performance, and regulatory requirements.

Could Velphoro be commercialized as an oral powder?

An oral powder or granule could improve dose flexibility and support pediatric use, but it would introduce new risks involving dust, segregation, taste exposure, dosing accuracy, and food compatibility.

Which excipient suppliers are best positioned for phosphate-binder products?

Suppliers with high-functionality cellulose, co-processed direct-compression systems, encapsulated flavors, silica-based flow aids, and mineral-compatible taste-masking technologies are best positioned. Their value depends on demonstrated performance with iron-containing, high-load formulations rather than general excipient availability.

References

1. U.S. Food and Drug Administration. (2024). Velphoro (sucroferric oxyhydroxide) chewable tablets: Prescribing information.
2. European Medicines Agency. (2024). Velphoro: EPAR product information.
3. Kidney Disease: Improving Global Outcomes. (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder. Kidney International Supplements, 7(1), 1-59.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
5. U.S. Food and Drug Administration. (2019). Draft guidance for industry: ANDAs for certain highly purified synthetic peptides.
6. CSL Limited. (2024). Annual report 2024.